Masimo

Masimo has received FDA 510(k) clearance for Root® with LiDCO® and the Masimo LiDCO Sensor, providing the ability to continuously monitor and trend oxygen delivery (DO₂).

By combining continuous Masimo SpHb® noninvasive hemoglobin, Masimo SET® oxygen saturation, and cardiac output, the solution provides clinicians with a more complete view of oxygen being delivered to the tissue.

Learn more: ow.ly/1iz250ZEZYy

#Masimo #LiDCO #PatientMonitoring #Hemodynamics less

Focused on execution. Grounded in patient impact.

At the J.P. Morgan Healthcare Conference, Masimo CEO Katie Szyman shared a clear vision for patient monitoring—disciplined execution, focused innovation, and technology that only matters if it improves patient care.

$MASI
#JPM26

In a feasibility study for a large, prospective, real-world trial, Masimo SET® pulse oximetry performed accurately on critically ill adult patients of all skin tones. Learn more: ow.ly/NwJG50X7pXZ

Tired of unreliable pulse oximetry during motion?
Masimo SET® was built to solve that.

With advanced algorithms and adaptive filters, SET® delivers accurate readings even during motion & low perfusion.

Learn why SET® is trusted by top U.S. hospitals: ow.ly/vIs550Wx5Ms

Today, we recognize #Juneteenth — a day of reflection, resilience, and progress.

Please join us at 11 AM PST for an informative session on “techquity,” how technology is shaping a future with equal care for all patients.

Register: ow.ly/SeOA50Wc0o5?